Sugi Predict

Sugi Predict / Compounds / SCHEMBL2255243

SCHEMBL2255243

SCHEMBL2255243

COC(=O)c1ccc(C)c[n+]1[O-]

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.47
▸ ALDH1A1 P00352 4/20 0.39
▸ MAPT P10636 1/20 0.39
▸ KMT2A Q03164 3/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ CYP2C9 P11712 2/20 0.37
▸ TCF4 P15884 1/20 0.37
▸ CTNNB1 P35222 1/20 0.37
▸ FFAR4 Q5NUL3 1/20 0.37
▸ POLB P06746 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ TSHR P16473 1/20 0.35
▸ NR4A2 P43354 2/20 0.35
▸ TP53 P04637 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29877642 1.00 TDP1 (0.47) TDP1ALDH1A1MAPTKMT2AMEN1
SCHEMBL31500519 0.83 MAPT (0.47) ALDH1A1MAPTKMT2AMEN1CYP2C9
SCHEMBL2944972 0.81 CA1 (0.47) TDP1ALDH1A1POLBSMN1; SMN2TSHR
SCHEMBL29550577 0.81 CA1 (0.47) TDP1ALDH1A1MAPTKMT2AMEN1
SCHEMBL1615851 0.81 CA1 (0.47) TDP1ALDH1A1MAPTKMT2AMEN1
SCHEMBL2593656 0.80 NPC1 (0.40) MAPTKMT2AMEN1POLBSMN1; SMN2
SCHEMBL2961818 0.80 SLC6A3 (0.38) TDP1ALDH1A1MAPTKMT2AMEN1
SCHEMBL17991548 0.79 TDP1 (0.48) TDP1ALDH1A1MAPTKMT2AMEN1
SCHEMBL14152686 0.79 HCAR2 (0.43) TDP1ALDH1A1KMT2AMEN1POLB
SCHEMBL13093861 0.79 MAPT (0.35) TDP1ALDH1A1MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250250269-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2025-08-07 — — US disclosed
US-20240317752-A1 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES BLACK DIAMOND THERAPEUTICS, INC. (US) 2024-09-26 — — US disclosed
CN-118239926-A TLR7 and 8 inhibitors, preparation method and application thereof 上海深势唯思科技有限责任公司 2024-06-25 — — CN disclosed
US-11891365-B2 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors VALO HEALTH, INC. (US) 2024-02-06 — — US disclosed
US-20220363651-A1 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS Valo Health, LLC 2022-11-17 — — US disclosed
WO-2022178256-A1 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES BLACK DIAMOND THERAPEUTICS, INC. (US) 2022-08-25 — — WO disclosed
US-11279681-B2 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors VALO HEALTH, INC. (US) 2022-03-22 — — US disclosed
CN-107873023-B 3-alkyl-4-amido-bicyclo [4, 5, 0] hydroxamic acids as HDAC inhibitors 福马治疗股份有限公司 2021-07-23 — — CN disclosed
US-10988450-B2 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors VALO EARLY DISCOVERY, INC. (US) 2021-04-27 — — US disclosed
US-10988450-B2 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors VALO EARLY DISCOVERY, INC. (US) 2021-04-27 — — US disclosed
US-7994179-B2 Carbamoyl compounds as DGAT1 inhibitors 190 ASTRAZENECA AB (SE) 2011-08-09 — — US disclosed
EP-2234978-A1 CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190 AstraZeneca AB (SE) 2010-10-06 — — EP disclosed
US-20090298853-A1 Carbamoyl Compounds as DGAT1 Inhibitors 190 ASTRAZENECA AB (SE) 2009-12-03 — — US disclosed
US-20090298853-A1 Carbamoyl Compounds as DGAT1 Inhibitors 190 ASTRAZENECA AB (SE) 2009-12-03 — — US disclosed
WO-2009081195-A1 CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190 ASTRAZENECA AB (SE) 2009-07-02 — — WO disclosed
WO-2009081195-A1 CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190 ASTRAZENECA AB (SE) 2009-07-02 — — WO disclosed
US-20090054428-A1 NOVEL PYRIMIDINE DERIVATIVES 965 ASTRAZENECA AB (SE) 2009-02-26 — — US disclosed
US-20090054428-A1 NOVEL PYRIMIDINE DERIVATIVES 965 ASTRAZENECA AB (SE) 2009-02-26 — — US disclosed
WO-2009010794-A1 2,4-DIAMINO-PYRIMIDINE DERIVATIVES ASTRAZENECA AB (SE) 2009-01-22 — — WO disclosed
WO-2009010794-A1 2,4-DIAMINO-PYRIMIDINE DERIVATIVES ASTRAZENECA AB (SE) 2009-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11279681-B2 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors HDAC1, HDAC4, HDAC2 TDP1 666/4885ALDH1A1 1465/4885MAPT 2816/4885
US-11891365-B2 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors HDAC1, HDAC4, HDAC2 TDP1 818/4885ALDH1A1 1918/4885MAPT 2560/4885
US-20240317752-A1 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES TYMP, DPYD, PNP TDP1 466/4885ALDH1A1 528/4885MAPT 4729/4885
US-20250250269-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, IAPP TDP1 2422/4885ALDH1A1 2171/4885MAPT 3395/4885
US-10988450-B2 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors HDAC1, HDAC4, HDAC2 TDP1 818/4885ALDH1A1 1918/4885MAPT 2560/4885
US-20220363651-A1 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS HDAC1, HDAC4, HDAC2 TDP1 818/4885ALDH1A1 1918/4885MAPT 2560/4885
US-20090054428-A1 NOVEL PYRIMIDINE DERIVATIVES 965 EPHB4, EPHB1, EPHB3 TDP1 835/4885ALDH1A1 1420/4885MAPT 3228/4885
US-20090298853-A1 Carbamoyl Compounds as DGAT1 Inhibitors 190 DGAT1, DGAT2, SOAT1 TDP1 3747/4885ALDH1A1 272/4885MAPT 2909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.